

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Neurizon Therapeutics Limited
ABN	35 094 006 023

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr. Michael Thurn
Date of last notice	26 March 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Dr Michael Joseph Thurn & Mrs Carmen Leeann Thurn <Thurn Family A/C> Mr Thurn is a beneficiary of the above holder which is the registered holder of the securities Dr Michael Thurn <Thurn Family A/C> Mr Thurn is a beneficiary of the above holder which is the registered holder of the securities
Date of change	30 April 2026

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<u>Indirect – Dr Michael Joseph Thurn & Mrs Carmen Leeann Thurn <Thurn Family A/C></u> - 3,487,720 fully paid ordinary shares - 500,000 Listed Options (NUZOA), expiring 30 April 2026 @ \$0.15 <u>Direct</u> - 1,140,000 Performance Rights expiring 30/06/2027 - 4,256,000 Unlisted Options, expiring 30/06/2032 @ \$0.20
Class	Listed Options (NUZOA), expiring 30 April 2026 @ \$0.15
Number acquired	-
Number disposed	<u>Indirect</u> 500,000 Listed Options (NUZOA), expiring 30 April 2026 @ \$0.15
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A
No. of securities held after change	<u>Indirect – Dr Michael Joseph Thurn & Mrs Carmen Leeann Thurn <Thurn Family A/C></u> - 3,487,720 fully paid ordinary shares <u>Direct</u> - 1,140,000 Performance Rights expiring 30/06/2027 - 4,256,000 Unlisted Options, expiring 30/06/2032 @ \$0.20

+ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of Listed Options (NUZOA).
--	-----------------------------------

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.